Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BeiGene, Ltd. (BGNE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/24/2023 8-K Quarterly results
07/11/2023 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio Highlights from early- and late-stage pipeline include"
05/09/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/09/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Receives New Approvals for BRUKINSA® in China BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide"
05/05/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/29/2023 8-K Quarterly results
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 8-K Quarterly results
Docs: "BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results",
"BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS® included for the first time XGEVA® successfully renewed",
"BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA in first-line and relapsed/refractory treatment settings"
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma"
12/19/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy